{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014866","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.141980+00:00","generated_at":"2026-05-30T03:36:54.778695+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024","bullets":["Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.","Cash, cash equivalents, and marketable securities $75.3M as of Sep 30, 2024; expected runway into H2 2026.","LNCB74 (B7-H4 ADC) IND planned by Q4 2024; preclinical data at SITC in November.","NC410 combo trial concluding, seeking partner; ovarian ICI-naïve response rate 25% (5/20) and CRC MSS 8.3% (3/36) PRs at 100 mg.","Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis) also seeking partner or financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014866","json":"https://secwatch.observer/filing/0001558370-24-014866.json","markdown":"https://secwatch.observer/filing/0001558370-24-014866.md","text":"https://secwatch.observer/filing/0001558370-24-014866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024014866/0001558370-24-014866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024014866/nxtc-20241107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:36:54.778695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}